Parliament watchdog wants sluggish value-based pricing discussion clarified by March
This article was originally published in Scrip
The UK Parliament’s Health Select Committee which monitors England's Department of Health, is calling for the department to work out plans for value-based pricing by the end of March. The lack of progress and clarity on the new arrangements so far, it said, is “unacceptable”.
You may also be interested in...
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.
Insurers argue that better use of real world data and multiple pricing assessments could help lower drug prices in Germany.
To keep investors happy, companies will have to start showing that their high-priced advanced therapies offset costs elsewhere in the health care system.